







Home ▶ All Journals ▶ Leukemia & Lymphoma ▶ List of Issues ▶ Volume 49, Issue 1 ▶ Hydroxyurea, azacitidine and gemtuzumab

Leukemia & Lymphoma > Volume 49, 2008 - Issue 11

587 51

Views CrossRef citations to date Altmetric

Original Articles: Clinical

Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial

Pages 2141-2147 | Received 16 Jun 2008, Accepted 27 Aug 2008, Published online: 01 Jul 2009

We Care About Your Privacy

We and our 855 partners store and access personal data, like browsing data or unique identifiers, on your device. Selecting "I Accept" enables tracking technologies to support the purposes shown under "we and our partners process data to provide," whereas selecting "Reject All" or withdrawing your consent will disable them. If trackers are disabled, some content and ads you see may not be as relevant to you. You can resurface this menu to change your choices or withdraw consent at any time by clicking the ["privacy preferences"] link on the bottom of the webpage [or the floating icon on the bottom-left of the webpage, if applicable]. Your choices will have effect within our Website. For more details, refer to our Privacy Policy. Here

We and our partners process data to provide:

and the second of the second o

I Accept

Reject All

Show Purpose

Repri

Full A



syndrom standard study, w gemtuzu

patients

The trea

olastic

6) to

this Phase II

е

ıp of


regimen.

blood cell

count below 10,000/µL, followed by azacitidine 75 mg/m² subcutaneously for 7 days and GO 3 mg/m² on day 8. Patients who achieved complete remission (CR) received a consolidation course. The median age of patients was 76 years. Eleven patients (55%) were treated in the outpatient setting. Fourteen (70%) achieved a CR, three of which were incomplete (CRi). The median duration of remission was 8 months and median survival was 10 months. Performance status of 0–1 was associated with high complete response rate. Overall toxicity was acceptable with only one (5%) early death due to disease progression. The combination of HU, azacitdine and GO appears to be a safe and effective regimen in the treatment of AML and high risk MDS in the elderly. These results need to be confirmed in a larger cohort of patients.

Q Keywords: Acute myeloid leukemia azacitidine gemtuzumab ozogamicin

Related research



Information for

Authors

Overview

R&D professionals

Open journals

Open access

Editors

Open Select

Librarians

Dove Medical Press

Societies

F1000Research

Opportunities

Help and information

Reprints and e-prints

Help and contact

Advertising solutions

Newsroom

Accelerated publication

All journals

Corporate access solutions

Books

Keep up to date

Register to receive personalised research and resources by email



Sign















Accessik



or & Francis Group

X